glp-1 drugs thyroid cancer Letter: Association Between Incretin Mimetics and Medullary GLP-1 Receptor Agonists and Carcinogenicity

Why this matters: Catching patterns early lets your clinician slow things down, tweak your dose, or give extra support

Together, they represent a holistic approach to enhancing our well-being

If the mice did not enter the target hole within 3 min, they were directed to the target and encouraged to enter

On the other hand, the risks of HHF (HR 0.93, 95% CI 0.831.04 with GLP-1RAs and HR 0.69, 95% CI 0.610.79 with SGLT2is) and composite kidney outcomes excluding macroalbuminuria (HR 0.92, 95% CI 0.801.06 with GLP-1RAs and HR 0.55, 95% CI 0.480.64 with SGLT2is) significantly reduced with SGLT2is only

For broader strategies on gentle hydration, you might also want to explore a key part of your overall hydration strategy

Future large long-term RCTs with primary or secondary outcomes, including thyroid disorders and real-world data, are needed to elucidate the association between GLP-1 receptor agonists and the risk of various thyroid disorders, particularly thyroid cancer